Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin Shoppe nearly doubles net income

This article was originally published in The Tan Sheet

Executive Summary

First-quarter net sales reach $191.6 million, up 11 percent, helping Vitamin Shoppe increase its net income 91.3 percent to $8.7 million. Diluted net income per share grew to 31 cents from 12 cents over first quarter 2009, Vitamin Shoppe said April 21. The North Bergen, N.J.-based company reported comparable same-store sales grew 6.2 percent, or $9.3 million, in the three months ended March 27, marking the 18 consecutive quarter of growth by that measure. Vitamin Shoppe, with 453 current locations, opened 16 stores in the January-March period and projects 42 total openings in 2010. Executive VP and Chief Financial Officer Michael Archbold said during a same-day earnings call that the firm projects mid-single-digit growth for comp-store sales for the year, with an expected degree of cannibalization as new locations open

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

Topics

UsernamePublicRestriction

Register

PS104050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel